Cell-Free RNA (cfRNA) Analysis Market

Cell-Free RNA (cfRNA) Analysis Market Analysis

The Cell-Free RNA Analysis Market size is estimated at USD 53.73 million in 2025, and is expected to reach USD 107.24 million by 2030, at a CAGR of 14.82% during the forecast period (2025-2030).

The cell-free RNA (cfRNA) analysis market refers to the commercial landscape encompassing the development, production, and utilization of technologies and services aimed at detecting, quantifying, and characterizing cfRNA molecules found in bodily fluids. The cfRNA analysis market is poised for growth due to technological advancements, increased interest in liquid biopsies, the rising burden of cancer, cardiovascular diseases, and neurological disorders, and ongoing research and development investments.

The increasing prevalence of diseases such as cancer and cardiovascular conditions drives demand for non-invasive diagnostic tools. For instance, according to an article published in the National Medical Journal of India in February 2024, it was observed that about 63 million people in India suffered from cardiovascular diseases in 2023, which was high compared to the last decade. In addition, cardiomyopathy, rheumatic heart disease, and right heart failure were the most prevalent categories of heart failure among the rural population in Chhattisgarh state of India. Thus, this market is driven by the increasing recognition of cfRNA as a valuable biomarker for various diseases, including cancer, cardiovascular diseases, and neurological disorders.

Furthermore, the shift towards minimally invasive diagnostic methods, such as liquid biopsies, is propelling the demand for cfRNA analysis. These methods allow for the detection of biomarkers without the need for invasive tissue biopsies.For instance, a study published in Human Genomics in October 2023 highlighted that liquid biopsy, the molecular analysis of body fluids, has emerged as a promising tool in cancer research, offering a more accessible assessment of patient health status than traditional tissue biopsies. Advancements in technology have enabled extensive genomic and transcriptomic analysis of DNA and RNA, especially in blood. Among the cell-free nucleic acids being studied, cell-free RNA (cfRNA) has garnered increasing attention for its tissue and cell-type specificity. Thus, such exploration of cfRNA in various diseases beyond cancer, such as cardiovascular diseases and neurological disorders, is expanding the market potential and applications of cfRNA analysis, thereby propelling to market growth.

Moreover, substantial investments in research and development by pharmaceutical and biotechnology firms drive advancements in cfRNA technologies. These advancements encompass the creation of novel assays and diagnostic instruments leveraging cfRNA. For example, in January 2022, Lucence, a precision oncology firm specializing in liquid biopsies for more precise cancer care, unveiled an enhanced version of its flagship LiquidHALLMARK liquid biopsy assay. This upgraded assay now incorporates cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling. Currently, the LiquidHALLMARK cfDNA and cfRNA assays are accessible to oncologists in the United States as laboratory-developed tests. Physicians actively employ these assays at centers designated by the National Cancer Institute (NCI) nationwide. Therefore, advancements in sequencing technologies and bioinformatics bolster the sensitivity and specificity of cfRNA analysis, paving the way for expanded growth opportunities in the market during the forecast period.

Hence, the studied market is posied to anticipated to grow over the forecast period owing to rising burden of cancer and other chronic diseases, growing preference for liquid biopsy, and ongoing innovations in the RNA technology field.

However, lack of skilled healthcare professionals and low market penetration may serve as an impediment for the studied market growth during the study period.

Cell-Free RNA (cfRNA) Analysis Market Trends

Oncology likely to Dominated the Market Throughout the Forecast Period

The rising incidence of cancer and the need for early detection and treatment monitoring drive the demand for cell-free RNA (cfRNA)-based diagnostics. These diagnostics provide valuable insights into tumor behavior and patient responses. For instance, a study published in June 2024 by the American Society of Clinical Oncology Educational Book, using GLOBOCAN data, projected a 109% increase in colorectal cancer (CRC) cases in low- and middle-income countries (LMICs) like Uruguay and Cuba by 2050. In contrast, high-income countries (HICs) such as the United States and several European nations expect a 41% increase in CRC cases by the same year. Given cfRNA's crucial role as a non-invasive biomarker in oncology for disease detection, monitoring, and prognosis, its importance is expected to drive the segment's growth in the coming years.

Furthermore, academic institutions and commercial research entities are conducting studies on cfRNA. For instance, a study published in August 2023 in Nature Biomedical Engineering, led by Assistant Professor of Biomolecular Engineering Daniel Kim, introduced an advanced RNA liquid biopsy platform. This platform detects traditional protein-coding RNA and the elusive 'RNA dark matter' in blood samples. Their findings, which show a significant improvement in liquid biopsy performance for cancer diagnosis, highlight the potential of cfRNA in transforming cancer diagnostics. Such innovative studies are anticipated to drive the segment's growth in the foreseeable future.

Moreover, innovations in sequencing technologies and bioinformatics are improving the sensitivity and specificity of cfRNA analysis. For instance, in February 2024, Takara Bio USA, Inc., a subsidiary of Takara Bio Inc., introduced two important solutions for oncology research. These automated kits for single-cell total RNA-seq and DNA-seq library preparation offer high sample and cell throughput, reduced hands-on time, and an enhanced capacity to capture information compared to existing technologies. The Shasta Total RNA-Seq Kit is designed to profile the full-length transcriptome of up to 100,000 single cells per run, enabling the detection of splicing isoforms, gene fusions, and non-polyadenylated RNAs. Consequently, as sequencing technologies and bioinformatics continue to advance, the utility of cfRNA analysis in cancer diagnostics and monitoring is set to expand, driving market growth.

Therefore, the increasing cancer burden, the growing demand for advanced diagnostic tools, and the promising potential of cfRNA in cancer research and clinical applications collectively indicate strong growth for this segment in the years ahead.

North America is Expected to Witness Significant Growth Over the Forecast Period

The cell-free RNA (cfRNA) analysis market in North America is set for substantial growth, driven by the escalating burden of cancer and infectious diseases, rising demand for prenatal screenings, and a broader shift towards non-invasive diagnostic techniques.

cfRNA analysis finds applications across diverse fields such as oncology, prenatal testing, and infectious diseases, enriching the market's diversity. For instance, a July 2024 study in Prenatal Diagnosis highlighted that the United States recorded an annual prenatal screening rate of 2.18 million in 2022. cfRNA analysis offers valuable insights into fetal health, including the identification of genetic disorders and developmental concerns. Consequently, with the increasing demand for prenatal screenings, cfRNA analysis is projected to rise in the coming years.

Additionally, the escalating cancer prevalence in North America serves as a significant catalyst. For instance, data from the Canadian Cancer Society in May 2024 revealed an estimated 30,500 new breast cancer cases among Canadian women, representing 25% of that year's female cancer diagnoses. Statistically, 1 in 8 Canadian women are likely to face a breast cancer diagnosis in their lifetime. As cancer diagnoses rise, so does the demand for effective diagnostic tools like cfRNA analysis.

Furthermore, the growing preference for minimally invasive diagnostic techniques, such as liquid biopsies, is boosting the demand for cfRNA analysis. For instance, a March 2024 article from Stanford University noted the revolutionary role of liquid biopsies in cancer diagnostics, allowing DNA detection from cancer cells via a simple blood test. Delving into cell-free RNA offers a deeper cancer characterization than DNA alone, as RNA reflects gene expression patterns that differ significantly across cancer types and can indicate cancer progression. Thus, given its less invasive nature than traditional biopsies, cfRNA analysis is becoming increasingly attractive for routine clinical applications, driving regional market growth.

Therefore, bolstered by the rising cancer burden, heightened interest in liquid biopsies, growing prenatal screening demand, and robust research and development investments, North America's cfRNA analysis market is on an upward trajectory.

Cell-Free RNA (cfRNA) Analysis Industry Overview

The cell-free RNA (cfRNA) analysis market is generally considered fragmented. This fragmentation arises from the presence of numerous players, including small and medium-sized companies and larger established firms, each offering various technologies and services related to cfRNA analysis. Some of the market players holding substantial shares are as follows: QIAGEN, Bio-Rad Laboratories, Inc., Promega Corporation, Norgen Biotek Corp, Zymo Research Corporation, and several others.

Cell-Free RNA (cfRNA) Analysis Market Leaders

Cell-Free RNA (cfRNA) Analysis Market News

• September 2024: PreAnalytiX GmbH, a joint venture between QIAGEN and BD (Becton, Dickinson, and Company), introduced the PAXgene Urine Liquid Biopsy Set. This set enables reliable analysis of cell-free DNA (cfDNA) from urine and is compatible with various molecular testing technologies such as qPCR, digital PCR, and next-generation sequencing (NGS). QIAGEN will commercialize the new set.
• September 2024: Researchers at Cornell have developed machine-learning models that use cell-free molecular RNA remnants to diagnose difficult-to-differentiate pediatric inflammatory conditions. This diagnostic tool can accurately identify whether a patient has Kawasaki disease (KD), Multisystem Inflammatory Syndrome in Children (MIS-C), a viral infection, or a bacterial infection while also monitoring the patient's organ health.